2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T61b,Caregiver burden is an often reported consequence of caring for patients with acute leukemia (AL). The current literature extensively describes caregiving tasks for patients with AL but provides limited information about the challenge of balancing these new obligations with previous and concurrent personal and family responsibilities. The goal of this qualitative study was to understand the multifaceted responsibilities of caregivers of patients with AL, their perceived impact, and the available resources that these caregivers found to be supportive in their caregiving role. A secondary analysis, using qualitative description, was conducted on data obtained from interviews with 21 caregivers of children and adults with AL. Caregivers described balancing many responsibilities related to the patient, other relationships, work, and home. Coordinating and multitasking responsibilities were perceived to have an adverse effect on the emotional, physical, and financial well-being of participants. Social support was identified as a resource that supported the ability to manage the diverse responsibilities, and caregivers provided emotional and practical suggestions for care. Upon becoming a caregiver for a patient with AL, individuals are faced with new responsibilities that compound their existing obligations, often resulting in the de-prioritization of the caregiver's needs and other responsibilities. The development and implementation of caregiver support as a standard of care is necessary to mitigate the negative consequences of caregiving.31:T608,Patients undergoing hematopoietic stem-cell transplantation (HSCT) or induction chemotherapy for acute leukemia (AL) generally receive a low-bacterial neutropenic diet (ND) to minimize infection from ingested microbes. Recent studies suggest that a more liberalized diet (LD) might be safe. However, those studies lacked robust designs to demonstrate noninferiority and did not address whether an LD improves caloric intake or nutritional status. This trial aimed to determine whether the rate of major infections in LD patients was noninferior to that in ND patients and whether an LD improved caloric intake and nutritional status. In this phase III noninferiority trial, patients were randomly assigned to either an ND or LD, containing fresh fruits and vegetables. The primary end point was the development of any major infection during neutropenia. The noninferiority margin was set at a difference of ≤10% in the major infection rate. The trial was halted at the second interim analysis after enrolling 214 evaluable patients, because of the LD arm's major infection rate surpassing the predefined stopping boundary. In the LD arm, major infections occurred in 31.4% of patients compared with 20.2% of patients in the ND arm, a difference of 11.2% ([95% CI, -0.4 to 22.9]; These findings suggest that LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit. Further dietary strategies are needed to improve nutrition without compromising safety.32:T9c0, PURPOSE Patients undergoing hematopoietic stem-cell transplantation (HSCT) or induction chemotherapy for acute leukemia (AL) generally receive a low-bacterial neutropenic diet (ND) to minimize infection from ingested microbes. Recent studies suggest that a more liberalized diet (LD) might be safe. However, those studies lacked robust designs to demonstrate noninferiority and did not address whether an LD improves caloric intake or nutritional status. This trial aimed to determine whether the rate of major infections in LD patients was noninferior to that in ND patients and whether an LD improved caloric intake and nutritional status. METHODS In this phase III noninferiority trial, patients were randomly assigned to either an ND or LD, containing fresh fruits and vegetables. The primary end point was the development of any major infection during neutropenia. The noninferiority margin was set at a difference of ≤10% in the major infection rate. RESULTS The trial was halted at the second interim analysis after enrolling 214 evaluable patients, because of the LD arm's major infection rate surpassing the predefined stopping boundary. In the LD arm, major infections occurred in 31.4% of patients compared with 20.2% of patients in the ND arm, a difference of 11.2% ([95% CI, –0.4 to 22.9]; P = .58). Furthermore, the caloric intake in the LD arm was not improved and nearly two thirds of patients on both diets reported critical nutritional problems. There was no advantage in symptoms, quality of life, or survival for the LD arm. CONCLUSION These findings suggest that LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit. Further dietary strategies are needed to improve nutrition without compromising safety. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Acute Leukemia: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Acute Leukemia (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Acute%20Leukemia\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Acute Leukemia\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Acute%20Leukemia\"}]}}"}}]],["$","$L2f",null,{"title":"Acute Leukemia: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Acute Leukemia with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1038/s41409-026-02914-0","pmid":"42237010","title":"Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee","journal_title":"Bone Marrow Transplantation","journal_issn":"0268-3369","published_at":"2026-06-03T00:00:00.000Z","url":"https://doi.org/10.1038/s41409-026-02914-0","source_score":13,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-11T13:42:51.118Z","updated_at":"2026-06-11T13:42:51.118Z","tags":[{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"condition","value":"Acute Leukemia","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"condition","value":"Hematological Malignancies","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"condition","value":"Lymphoma","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"condition","value":"Multiple Myeloma","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"modality","value":"Cellular Therapy","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"modality","value":"Hematopoietic Stem Cell Transplantation","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"modality","value":"Immunotherapy","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"modality","value":"Targeted Therapy","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"study_design","value":"Expert Consensus / Clinical Practice Guidelines","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"warning","value":"No sample size applies — this is a consensus framework, not a patient-level study.","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"warning","value":"Study design is expert consensus/guidelines; no empirical validation data are reported, so level of evidence is assigned as 5 (expert opinion).","value_numeric":null},{"paper_doi":"10.1038/s41409-026-02914-0","tag_type":"warning","value":"The framework covers acute leukemias, lymphomas, and multiple myeloma but does not explicitly address all hematological malignancies (e.g., CLL, MDS); generalizability beyond the stated scope is unclear.","value_numeric":null}],"summaries":{"what_studied":"The EBMT Practice Harmonisation and Guidelines Committee developed a standardized framework for defining and recording 'lines of therapy' (LoT) across acute leukemias, lymphomas, and multiple myeloma, addressing wide variability in current practice.","key_result":"A LoT is defined as a coherent therapeutic episode aimed at achieving or maintaining disease control; a new LoT is triggered by progression, relapse, refractory disease, or introduction of an agent from a distinct therapeutic class — but not by dose adjustments, schedule changes, or toxicity-driven omissions. Bridging therapies before CAR-T or transplant are counted within the same LoT as the definitive treatment.","limitations":"This is a consensus framework document rather than an empirically validated study; real-world applicability and inter-rater reliability of the proposed definitions have not been tested prospectively.","practice_takeaway":"When documenting treatment history or enrolling patients in registries and trials, use this EBMT framework to assign LoT: count a new line only at progression/relapse/refractory disease or when a new therapeutic class is added, not at routine dose or schedule changes. Treat bridging therapy before CAR-T or stem cell transplant as part of the same LoT as the cellular therapy."}},{"doi":"10.1007/s15010-026-02824-9","pmid":"42201513","title":"Efficacy of fluoroquinolone prophylaxis in high-risk neutropenic patients with haematological malignancies: a systematic review with meta-analysis","journal_title":"Infection","journal_issn":"0300-8126","published_at":"2026-05-27T00:00:00.000Z","url":"https://doi.org/10.1007/s15010-026-02824-9","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-31T13:35:34.497Z","updated_at":"2026-05-31T13:35:34.497Z","tags":[{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"condition","value":"Acute Leukemia","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"condition","value":"Febrile Neutropenia","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"condition","value":"Haematological Malignancy","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"condition","value":"Multiple Myeloma","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"generic","value":"ciprofloxacin","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"generic","value":"levofloxacin","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"modality","value":"Fluoroquinolone Antibiotic Prophylaxis","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"sample_size","value":"n=12586","value_numeric":12586},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"study_design","value":"Systematic Review with Meta-Analysis","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"warning","value":"All 18 included studies were published 2015–2025 — none overlap with the prior Mikulska 2018 meta-analysis, which covered up to 2014, so this is a fully contemporary but non-overlapping evidence base.","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"warning","value":"Fluoroquinolone-resistant strain outcome is based on only 6 small studies with very high heterogeneity (I²=78%); the null finding should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"warning","value":"Pediatric and ciprofloxacin subgroups are underrepresented; findings may not generalize to those populations.","value_numeric":null},{"paper_doi":"10.1007/s15010-026-02824-9","tag_type":"warning","value":"The confidence interval for the febrile episode RR (reported as 0.88–0.96) is internally inconsistent with the point estimate of 0.87 — likely a typographical error in the source abstract; the p-value (0.006) supports a real effect.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and meta-analysis of 18 studies (12,586 patients) comparing fluoroquinolone prophylaxis (ciprofloxacin or levofloxacin) vs. no prophylaxis in high-risk neutropenic adults and children with haematological malignancies or undergoing HSCT; studies published 2015–2025.","key_result":"Prophylaxis reduced febrile episodes (RR 0.87, p=0.006) and bloodstream infections (RR 0.59, p<0.001) but did **not** reduce overall mortality (RR 1.04, 95% CI 0.79–1.37, p=0.77). No significant difference in fluoroquinolone-resistant strain isolation was seen (RR 0.87, p=0.77), though this outcome was reported in only 6 studies with high heterogeneity (I²=78%).","limitations":"- Most included studies were retrospective (12/18), introducing selection bias.\n- Follow-up duration varied widely (21–365 days), complicating mortality comparisons.\n- Resistance outcome was underpowered: only 6 studies, 1,481 patients, and high heterogeneity (I²=78%) — cannot rule out long-term resistance impact.","practice_takeaway":"Fluoroquinolone prophylaxis (preferably levofloxacin) reduces fever and bacteremia in high-risk neutropenic haematology patients but does not improve survival — so decisions should weigh local fluoroquinolone resistance rates (e.g., >34% *E. coli* resistance in some regions) and individual patient risk before routine use."}},{"doi":"10.1200/jco-25-02510","pmid":"42044462","title":"Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-04-27T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-02510","source_score":121,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T22:51:18.454Z","updated_at":"2026-05-07T22:51:18.454Z","tags":[{"paper_doi":"10.1200/jco-25-02510","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"condition","value":"Acute Leukemia","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"condition","value":"Hematologic Malignancy","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"generic","value":"dilanubicel","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"generic","value":"mycophenolate mofetil","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"modality","value":"Cord Blood Transplantation","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"modality","value":"Expanded Progenitor Cell Therapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"sample_size","value":"n=28","value_numeric":28},{"paper_doi":"10.1200/jco-25-02510","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"study_design","value":"Phase II Clinical Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"warning","value":"Dilanubicel is an investigational product and is not currently approved for routine clinical use; phase II data should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"warning","value":"The age range (10–63 years) spans pediatric and adult populations, making age-group classification 'mixed'; pediatric-specific outcomes are not reported separately.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02510","tag_type":"warning","value":"The comparator group was a non-randomized contemporaneous cohort; differences in patient selection or conditioning may confound outcome comparisons.","value_numeric":null}],"summaries":{"what_studied":"This single-center phase II trial evaluated the safety and clinical outcomes of adding dilanubicel — a cryopreserved, pooled-donor, non-HLA-matched expanded progenitor cell product — to single-unit cord blood transplantation (CBT) in 28 patients with hematologic malignancies, with a median follow-up of 1.4 years.","key_result":"All 28 patients achieved neutrophil engraftment (median 18 days) and platelet engraftment (median 31 days); no grade 3–4 acute or chronic GVHD was observed; and 27 of 28 patients remained alive and disease-free at follow-up. Compared to a contemporaneous cohort receiving standard single- or double-unit CBT, the dilanubicel group had faster hematopoietic recovery and markedly lower severe acute GVHD rates.","limitations":"- Small single-center cohort (n=28) limits generalizability and statistical power.\n- The comparator was a non-randomized contemporaneous institutional cohort, introducing selection bias.\n- Median follow-up of 1.4 years may be insufficient to capture late relapse or chronic GVHD events.","practice_takeaway":"Adding dilanubicel to single-unit CBT appears safe — with no severe GVHD — and may speed engraftment, potentially reducing the need for double-unit grafts. Clinicians should await larger, randomized trials before adopting this approach broadly."}},{"doi":"10.1182/blood.2025031201","pmid":"41849234","title":"Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-03-18T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025031201","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-11T13:26:23.172Z","updated_at":"2026-08-11T13:26:23.172Z","tags":[{"paper_doi":"10.1182/blood.2025031201","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"brand","value":"Ziftomenib","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"condition","value":"Acute Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"condition","value":"KMT2A-Rearranged Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"condition","value":"NPM1-Mutated Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"generic","value":"revumenib","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"generic","value":"ziftomenib","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"modality","value":"Menin-KMT2A Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"study_design","value":"Preclinical Study","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"warning","value":"No sample size (N) is reported for a single unified cohort — multiple model systems were used; a sample_size tag was omitted accordingly.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"warning","value":"Publication date (2026-03-18) is in the future relative to most current training data; FDA approval of ziftomenib for NPM1-mutated AML is stated in the abstract as a completed event.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031201","tag_type":"warning","value":"Study is entirely preclinical (in vitro and animal models); clinical outcomes data are not reported. The 'practice_changing' impact flag reflects FDA approval context mentioned in the abstract, not a clinical trial result within this paper.","value_numeric":null}],"summaries":{"what_studied":"Ziftomenib, an oral small-molecule inhibitor of the menin–KMT2A protein-protein interaction, was evaluated in preclinical models of acute leukemia (KMT2A-rearranged, NPM1-mutated, NUP98-rearranged) — including cell lines, primary patient samples, xenografts, and patient-derived xenografts — and also tested against four MEN1 resistance mutations (T349M, M327I, G331R, G331D) identified from clinical experience with revumenib.","key_result":"Ziftomenib potently inhibited proliferation, reduced clonogenic potential, and induced differentiation in menin–KMT2A–dependent leukemia cells, with strong downregulation of target genes (MEIS1, HOXA9, HOXB2); it retained activity against T349M and G331R mutants (50% growth inhibition ≤25 nM for G331R), while M327I and G331D mutants were resistant. In vivo, ziftomenib induced leukemia regression or reduced burden in KMT2A-rearranged xenograft and PDX models.","limitations":"All efficacy data are preclinical (cell lines, xenografts, PDX); no head-to-head clinical comparison with revumenib is provided. Resistance mutant findings are based on in vitro models and may not fully reflect clinical resistance patterns. The study does not report pharmacokinetic or safety data from clinical trials.","practice_takeaway":"Ziftomenib has received FDA approval for adult NPM1-mutated AML and shows preclinical activity against some revumenib-resistance mutations (T349M, G331R), but not M327I or G331D — clinicians should be aware that not all MEN1 mutations confer cross-resistance. Ongoing clinical trials are evaluating ziftomenib in KMT2A-rearranged and NPM1-mutated leukemias as monotherapy and in combinations."}},{"doi":"10.1016/j.leukres.2025.108154","pmid":"41513502","title":"Juggling two worlds: Exploring the experiences of caregivers of patients with acute leukemia","journal_title":"Leukemia Research","journal_issn":"0145-2126","published_at":"2026-01-10T00:00:00.000Z","url":"https://doi.org/10.1016/j.leukres.2025.108154","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-12","doi":"10.1016/j.leukres.2025.108154","days":"7","issn":"0145-2126","rank":"8","field":"Clinical Medicine","score":"15","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1016/j.leukres.2025.108154","title":"Juggling two worlds: Exploring the experiences of caregivers of patients with acute leukemia.","journal":"Leukemia research","methods":"","results":"Caregivers described balancing many responsibilities related to the patient, other relationships, work, and home. Coordinating and multitasking responsibilities were perceived to have an adverse effect on the emotional, physical, and financial well-being of participants. Social support was identified as a resource that supported the ability to manage the diverse responsibilities, and caregivers provided emotional and practical suggestions for care.","abstract":"$30","keywords":["Acute leukemia","Caregiver burden","Caregivers","Qualitative study"],"pubmed_id":"41513502","conclusions":"","publication_date":"2026-01-10T00:00:00"},"crossref":{"DOI":"10.1016/j.leukres.2025.108154","URL":"https://doi.org/10.1016/j.leukres.2025.108154","ISSN":["0145-2126"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0145212625006447?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0145212625006447?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"108154","type":"journal-article","issue":null,"score":1,"title":["Juggling two worlds: Exploring the experiences of caregivers of patients with acute leukemia"],"author":[{"given":"Maya A.","family":"Stern","sequence":"first","affiliation":[]},{"given":"Elizaveta","family":"Klekovkina","sequence":"additional","affiliation":[]},{"given":"Stephanie M.","family":"Nanos","sequence":"additional","affiliation":[]},{"given":"Esme","family":"Fuller-Thomson","sequence":"additional","affiliation":[]},{"given":"Carmine","family":"Malfitano","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/501100017559","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100017559","name":"The Garron Family Cancer Centre","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100000024","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2026-01-08T11:20:13Z","timestamp":1767871213000,"date-parts":[[2026,1,8]]},"indexed":{"date-time":"2026-01-16T06:01:58Z","timestamp":1768543318618,"date-parts":[[2026,1,16]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://doi.org/10.15223/policy-017","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-037","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-012","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-029","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-004","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"stm-asf"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0145212625006447"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Juggling two worlds: Exploring the experiences of caregivers of patients with acute leukemia"},{"name":"journaltitle","label":"Journal Title","value":"Leukemia Research"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.leukres.2025.108154"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies."}],"deposited":{"date-time":"2026-01-15T12:48:36Z","timestamp":1768481316000,"date-parts":[[2026,1,15]]},"issn-type":[{"type":"print","value":"0145-2126"}],"published":{"date-parts":[[2026,1]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/j.mpmed.2021.02.004","key":"10.1016/j.leukres.2025.108154_bib1","year":"2021","issue":"5","author":"Okikiolu","volume":"49","first-page":"274","unstructured":null,"article-title":"Acute leukaemia","journal-title":"Medicine","doi-asserted-by":"crossref"},{"DOI":"10.3390/cancers13092256","key":"10.1016/j.leukres.2025.108154_bib2","year":"2021","issue":null,"author":"Tebbi","volume":null,"first-page":null,"unstructured":null,"article-title":"Etiology of Acute Leukemia: A Review","journal-title":"Cancers [Internet]","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10880-016-9459-6","key":"10.1016/j.leukres.2025.108154_bib3","year":"2016","issue":"3","author":"Pailler","volume":"23","first-page":"298","unstructured":null,"article-title":"Adjustment to Acute Leukemia: The Impact of Social Support and Marital Satisfaction on Distress and Quality of Life Among Newly Diagnosed Patients and Their Caregivers","journal-title":"J. Clin. Psychol. Med. Settings","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib4","year":"2022","issue":"20","author":"Dinsmore","volume":"31","first-page":"1020","unstructured":null,"article-title":null,"journal-title":"Psychol. Psychosoc. Emot. Wellbeing Child. Young.. People Leuk.","doi-asserted-by":null},{"DOI":"10.1002/pon.2092","key":"10.1016/j.leukres.2025.108154_bib5","year":"2013","issue":"2","author":"Rodin","volume":"22","first-page":"299","unstructured":null,"article-title":"Traumatic stress in acute leukemia","journal-title":"PsychoOncol.","doi-asserted-by":"crossref"},{"DOI":"10.1188/14.ONF.286-295","key":"10.1016/j.leukres.2025.108154_bib6","year":"2014","issue":"3","author":"Albrecht","volume":"41","first-page":"286","unstructured":null,"article-title":"Physiologic and Psychological Symptoms Experienced by Adults With Acute Leukemia: An Integrative Literature Review","journal-title":"Oncol. Nurs. Forum","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib7","year":"2013","issue":"0 11","author":"Romito","volume":"119","first-page":null,"unstructured":null,"article-title":"Informal Caregiving for Cancer Patients","journal-title":"Cancer","doi-asserted-by":null},{"DOI":"10.1136/bmjopen-2022-065422","key":"10.1016/j.leukres.2025.108154_bib8","year":"2022","issue":"11","author":"Jibb","volume":"12","first-page":null,"unstructured":null,"article-title":"Traumatic stress symptoms in family caregivers of patients with acute leukaemia: protocol for a multisite mixed methods, longitudinal, observational study","journal-title":"BMJ Open","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib9","year":"2017","issue":null,"author":"Hunt","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Cancer Caregiving U. S. Intense Episodic Challenging Care Experience","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib10","year":"2020","issue":"4","author":"Liu","volume":"7","first-page":"438","unstructured":null,"article-title":"Caregiver burden: A concept analysis","journal-title":"Int. J. Nurs. Sci.","doi-asserted-by":null},{"DOI":"10.4103/ipj.ipj_75_18","key":"10.1016/j.leukres.2025.108154_bib11","year":"2018","issue":"2","author":"Kumari","volume":"27","first-page":"249","unstructured":null,"article-title":"Burden of caregiving and its impact in the patients of acute lymphoblastic leukemia","journal-title":"Ind. Psychiatry J.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib12","year":"2016","issue":"10","author":"Oberoi","volume":"24","first-page":"4177","unstructured":null,"article-title":"Caregivers’ information needs and their “experiences of care” during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors. Supportive care in cancer","journal-title":"Off. J. Multinatl. Assoc. Support. Care Cancer","doi-asserted-by":null},{"DOI":"10.1093/annonc/mdw205","key":"10.1016/j.leukres.2025.108154_bib13","year":"2016","issue":"8","author":"Nipp","volume":"27","first-page":"1607","unstructured":null,"article-title":"Factors associated with depression and anxiety symptoms in family caregivers of patients with incurable cancer. Annals of oncology","journal-title":"Off. J. Eur. Soc. Med. Oncol.","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12325-021-01872-x","key":"10.1016/j.leukres.2025.108154_bib14","year":"2021","issue":"10","author":"Yucel","volume":"38","first-page":"5002","unstructured":null,"article-title":"Health-Related and Economic Burden Among Family Caregivers of Patients with Acute Myeloid Leukemia or Hematological Malignancies","journal-title":"Adv. Ther.","doi-asserted-by":"crossref"},{"DOI":"10.1017/S1478951521000389","key":"10.1016/j.leukres.2025.108154_bib15","year":"2022","issue":"1","author":"Kastrinos","volume":"20","first-page":"22","unstructured":null,"article-title":"A lifespan approach to understanding family caregiver experiences of a blood cancer diagnosis","journal-title":"Palliat. Support. Care","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0216821","key":"10.1016/j.leukres.2025.108154_bib16","year":"2019","issue":"5","author":"Jepsen","volume":"14","first-page":null,"unstructured":null,"article-title":"Living with outpatient management as spouse to intensively treated acute leukemia patients","journal-title":"PLOS ONE","doi-asserted-by":"crossref"},{"DOI":"10.1007/s11764-023-01384-3","key":"10.1016/j.leukres.2025.108154_bib17","year":"2024","issue":"1","author":"Cho","volume":"18","first-page":"68","unstructured":null,"article-title":"Making sense of the cancer journey: Pediatric cancer survivors’ and their parents’ autobiographical memories","journal-title":"Journal cancer survivorship research practice","doi-asserted-by":"crossref"},{"DOI":"10.53350/pjmhs22167820","key":"10.1016/j.leukres.2025.108154_bib18","year":"2022","issue":"07","author":"Kanchanaudom","volume":"16","first-page":"820","unstructured":null,"article-title":"Caring for Pediatric Patients with Acute Lymphoblastic Leukemia of Caregivers: Qualitative Study","journal-title":"Pak. J. Med. Health Sci.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib19","year":"2024","issue":null,"author":"Yu","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Prelim. Qual. Eval. Emot. SymptomFocus. Engagem. (EASE) Psychother. Interv. Fam. Caregiv. Child. Acute Leuk.","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib20","year":"2022","issue":null,"author":"Malfitano","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":"Distress Fam. Caregiv. Individ. Recent. Diagn. Acute Leuk. a Ground Theory Study","doi-asserted-by":null},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib21","year":"2022","issue":null,"author":"Government of Canada IAP on RE","volume":"2","first-page":null,"unstructured":null,"article-title":null,"journal-title":"TriCounc. Policy Statement. Ethic.. Conduct Res. Involv. Hum. TCPS","doi-asserted-by":null},{"DOI":"10.3390/socsci8090255","key":"10.1016/j.leukres.2025.108154_bib22","year":"2019","issue":"9","author":"Kaushik","volume":null,"first-page":"255","unstructured":null,"article-title":"Pragmatism as a Research Paradigm and Its Implications for Social Work Research","journal-title":"Soc. Sci.","doi-asserted-by":"crossref"},{"DOI":"10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G","key":"10.1016/j.leukres.2025.108154_bib23","year":"2000","issue":"4","author":"Sandelowski","volume":"23","first-page":"334","unstructured":null,"article-title":"Whatever happened to qualitative description?","journal-title":"Res. Nurs. Health","doi-asserted-by":"crossref"},{"DOI":"10.1177/2333393617742282","key":"10.1016/j.leukres.2025.108154_bib24","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Bradshaw C., Atkinson S., Doody O. Employing a Qualitative Description Approach in Health Care Research. https://doi-org.myaccess.library.utoronto.ca/101177/2333393617742282 [Internet]. 2017 Nov 24 [cited 2024 Oct 30];4. Available from: https://journals-sagepub-com.myaccess.library.utoronto.ca/doi/full/10.1177/2333393617742282.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib25","year":"2014","issue":null,"author":"Creswell","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2307/2092933","key":"10.1016/j.leukres.2025.108154_bib26","year":"1960","issue":"4","author":"Goode","volume":"25","first-page":"483","unstructured":null,"article-title":"A Theory of Role Strain","journal-title":"Am. Sociol. Rev.","doi-asserted-by":"crossref"},{"DOI":"10.1002/pon.1013","key":"10.1016/j.leukres.2025.108154_bib27","year":"2006","issue":"9","author":"Kim","volume":"15","first-page":"795","unstructured":null,"article-title":"Psychological adjustment of cancer caregivers with multiple roles","journal-title":"PsychoOncol.","doi-asserted-by":"crossref"},{"DOI":"10.1145/3359255","key":"10.1016/j.leukres.2025.108154_bib28","year":"2019","issue":"CSCW","author":"Seo","volume":"3","first-page":"1","unstructured":null,"article-title":"Balancing tensions between caregiving and parenting responsibilities in pediatric patient care","journal-title":"Proc. ACM Hum. Comput. Interact.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib29","year":"2021","issue":"6","author":"Fisher","volume":"29","first-page":"3069","unstructured":null,"article-title":"Home wasn’t really home anymore”: Understanding caregivers’ perspectives of the impact of blood cancer caregiving on the family system","journal-title":"Support. Care Cancer","doi-asserted-by":null},{"DOI":"10.1097/NCC.0000000000001054","key":"10.1016/j.leukres.2025.108154_bib30","year":"2022","issue":"5","author":"Nielsen","volume":"45","first-page":"E801","unstructured":null,"article-title":"Experiences and Needs of Caregivers of Adult Patients With Hematologic Malignancies During Treatment: A Qualitative Longitudinal Study","journal-title":"Cancer Nurs.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib31","year":"2013","issue":null,"author":"Turcotte","volume":null,"first-page":null,"unstructured":null,"article-title":"Statistics Canada","journal-title":"Fam. Caregiving What are Conséq.","doi-asserted-by":null},{"DOI":"10.1182/blood-2018-99-118205","key":"10.1016/j.leukres.2025.108154_bib32","year":"2018","issue":null,"author":"Capodanno","volume":"132","first-page":"5867","unstructured":null,"article-title":"Home Care of Acute Leukemia Patients: From Active Therapy to End-of-Life and Palliative Care. a Three-Year Experience of a Single Centre","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ejon.2022.102200","key":"10.1016/j.leukres.2025.108154_bib33","year":"2022","issue":null,"author":"Bennich","volume":"61","first-page":null,"unstructured":null,"article-title":"The significance of home-based portable pump chemotherapy for family caregivers to newly diagnosed patients with acute myeloid leukemia: a qualitative thematic analysis","journal-title":"Eur. J. Oncol. Nurs.","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/j.leukres.2025.108154_bib34","year":"2014","issue":"6","author":"Cheng","volume":"26","first-page":"371","unstructured":null,"article-title":"Secondary analysis of existing data: opportunities and implementation","journal-title":"Shanghai Arch. Psychiatry","doi-asserted-by":null},{"DOI":"10.1080/07347332.2020.1796887","key":"10.1016/j.leukres.2025.108154_bib35","year":"2020","issue":"6","author":"Junkins","volume":"38","first-page":"782","unstructured":null,"article-title":"Cancer across the ages: a narrative review of caregiver burden for patients of all ages","journal-title":"J. Psychosoc. Oncol.","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0145212625006447"],"article-number":"108154","content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,1]]},"reference-count":35,"published-online":null,"references-count":35,"short-container-title":["Leukemia Research"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.leukres.2025.108154","is_oa":false,"title":"Juggling two worlds: Exploring the experiences of caregivers of patients with acute leukemia","updated":"2026-01-10T04:46:20+00:00","published_date":"2026-01-01","best_oa_location":null}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"condition","value":"Acute Leukemia","value_numeric":null},{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"sample_size","value":"n=21","value_numeric":21},{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"study_design","value":"Qualitative Study","value_numeric":null},{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"warning","value":"Age group refers to the patients (children and adults); caregiver ages were not reported.","value_numeric":null},{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"warning","value":"Design classification is based on an abstract of a qualitative secondary analysis.","value_numeric":null},{"paper_doi":"10.1016/j.leukres.2025.108154","tag_type":"warning","value":"Findings are descriptive from interviews; no quantitative outcomes were reported.","value_numeric":null}],"summaries":{"what_studied":"A secondary qualitative analysis of interviews with 21 caregivers of children and adults with acute leukemia explored their responsibilities, perceived impacts, and supportive resources.","key_result":"Caregivers reported juggling patient care, relationships, work, and home; coordinating and multitasking were perceived to harm emotional, physical, and financial well-being, while social support helped them manage these demands and informed emotional and practical suggestions for care.","limitations":"Secondary analysis of prior interviews with a small sample (n=21) that included caregivers across pediatric and adult contexts.","practice_takeaway":"Expect caregiver needs to be deprioritized amid competing duties; integrate structured caregiver support as part of routine leukemia care to mitigate emotional, physical, and financial strain."}},{"doi":"10.1200/jco-25-00889","pmid":"41406403","title":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2025-12-17T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-00889","source_score":269,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-22","doi":"10.1200/jco-25-00889","days":"30","issn":"0732-183X","rank":"3","field":"Clinical Medicine","score":"269","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1200/JCO-25-00889","title":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","methods":"","results":"The trial was halted at the second interim analysis after enrolling 214 evaluable patients, because of the LD arm's major infection rate surpassing the predefined stopping boundary. In the LD arm, major infections occurred in 31.4% of patients compared with 20.2% of patients in the ND arm, a difference of 11.2% ([95% CI, -0.4 to 22.9]; ","abstract":"$31","keywords":[],"pubmed_id":"41406403","conclusions":"These findings suggest that LD is not a safe alternative to ND in HSCT patients and patients with AL because of increased infection risk without nutritional or other benefit. Further dietary strategies are needed to improve nutrition without compromising safety.","publication_date":"2025-12-17T00:00:00"},"crossref":{"DOI":"10.1200/jco-25-00889","URL":"https://doi.org/10.1200/jco-25-00889","ISSN":["0732-183X","1527-7755"],"link":[{"URL":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-00889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia"],"author":[{"given":"John R.","family":"Wingard","sequence":"first","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Ji-Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Florida, Gainesville, FL"},{"name":"Division of Quantitative Sciences, University of Florida Health Cancer Center, Gainesville, FL"}]},{"given":"Derek","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Quantitative Sciences, University of Florida Health Cancer Center, Gainesville, FL"}]},{"given":"Zeina","family":"Al-Mansour","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Nosha","family":"Farhadfar","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Jack","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"John","family":"Hiemenz","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Erin A.","family":"Dean","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA"}]},{"given":"Randy","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Gaurav","family":"Trikha","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Jenna N.","family":"Schulz","sequence":"additional","affiliation":[{"name":"University of Florida Health, Food and Nutrition, Gainesville, FL"}]},{"given":"Christina L.","family":"Cline","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"},{"name":"Clinical Research Office, University of Florida Health Cancer Center, Gainesville, FL"}]},{"given":"Helen","family":"Leather","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Michele W.","family":"Sugrue","sequence":"additional","affiliation":[{"name":"Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, FL"}]},{"given":"Wendy J.","family":"Dahl","sequence":"additional","affiliation":[{"name":"Department of Food Science and Human Nutrition, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL"}]},{"given":"Kristina H.","family":"McGee","sequence":"additional","affiliation":[{"name":"University of Florida Health, Food and Nutrition, Gainesville, FL"}]},{"given":"Alex","family":"Leggett","sequence":"additional","affiliation":[{"name":"Clinical Research Office, University of Florida Health Cancer Center, Gainesville, FL"}]},{"given":"Debra Lynch","family":"Kelly","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Florida, Gainesville, FL"},{"name":"Loewenberg College of Nursing, University of Memphis, Memphis, TN"}]}],"issued":{"date-parts":[[2025,12,17]]},"member":"233","prefix":"10.1200","source":"Crossref","volume":null,"created":{"date-time":"2025-12-17T21:00:51Z","timestamp":1766005251000,"date-parts":[[2025,12,17]]},"indexed":{"date-time":"2025-12-17T21:05:41Z","timestamp":1766005541989,"date-parts":[[2025,12,17]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://ascopubs.org/doi/10.1200/JCO-25-00889"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-04-17"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2025-08-27"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-11-05"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-12-17"}],"deposited":{"date-time":"2025-12-17T21:00:53Z","timestamp":1766005253000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"published":{"date-parts":[[2025,12,17]]},"publisher":"American Society of Clinical Oncology (ASCO)","reference":[{"DOI":"10.1038/sj.bmt.1702447","key":"e_1_3_11_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.1997.15.6.2254","key":"e_1_3_11_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0891-5520(05)70157-4","key":"e_1_3_11_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.hoc.2010.11.008","key":"e_1_3_11_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cid/cir073","key":"e_1_3_11_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1004383","key":"e_1_3_11_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/MOH.0b013e32834da9bf","key":"e_1_3_11_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0002-8223(21)38798-3","key":"e_1_3_11_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0002-8223(01)00292-9","key":"e_1_3_11_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clnu.2021.02.030","key":"e_1_3_11_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/01635581.2019.1606262","key":"e_1_3_11_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmjspcare-2018-001742","key":"e_1_3_11_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_14_2","year":"2016","issue":null,"author":"van Dalen EC","volume":"4","first-page":"Cd006247","unstructured":"van Dalen EC, Mank A, Leclercq E, et al: Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 4:Cd006247, 2016","article-title":"Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.3389/fonc.2022.836371","key":"e_1_3_11_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/sj.bmt.1705493","key":"e_1_3_11_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1159/000449451","key":"e_1_3_11_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00520-017-3716-6","key":"e_1_3_11_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/bmt.2014.228","key":"e_1_3_11_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3109/10428194.2013.853766","key":"e_1_3_11_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/ecc.12262","key":"e_1_3_11_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2014.01.030","key":"e_1_3_11_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2015.04.016","key":"e_1_3_11_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2014-02-554725","key":"e_1_3_11_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"U.S. Food and Drug Administration: Food Code 2022. College Park MD U.S. Department of Health and Human Services 2022","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_11_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Food and Drug Administration: Buy store and serve safe food. https://www.fda.gov/food/consumers/buy-store-serve-safe-food","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_11_27_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"2025 NHSN Laboratory Confirmed Bloodstream Infection (LCBI) checklist. https://www.cdc.gov/nhsn/pdfs/checklists/2025-NHSN-Laboratory-Confirmed-Bloodstream-Infection-LCBI-Checklist.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1093/cid/ciw353","key":"e_1_3_11_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cid/ciw668","key":"e_1_3_11_29_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cid/ciu134","key":"e_1_3_11_30_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1086/588660","key":"e_1_3_11_31_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1071/HI11011","key":"e_1_3_11_32_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cid/cis998","key":"e_1_3_11_33_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_34_2","year":"2024","issue":null,"author":"Schulz JN","volume":null,"first-page":"1","unstructured":"Schulz JN, McGee KH, Weaver MT, et al: A liberalized diet does not improve caloric intake during neutropenia in patients undergoing hematopoietic stem cell transplants. Nutr Clin Pract:1-12, 2024","article-title":"A liberalized diet does not improve caloric intake during neutropenia in patients undergoing hematopoietic stem cell transplants","journal-title":"Nutr Clin Pract","doi-asserted-by":null},{"DOI":"10.1080/01635581.2013.755554","key":"e_1_3_11_35_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_36_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Ottery F: Scored patient-generated subjective global assessment (PG-SGA). http://pt-global.org/wp-content/uploads/2014/09/PG-SGA-Sep-2014-teaching-document-140914.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1097/MD.0000000000038402","key":"e_1_3_11_37_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","key":"e_1_3_11_38_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.24920","key":"e_1_3_11_39_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_40_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Cleeland C: The MD Anderson Symptom inventory (MDASI). https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/symptom-research/symptom-assessment-tools/md-anderson-symptom-inventory.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1634/theoncologist.2010-0193","key":"e_1_3_11_41_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.02775","key":"e_1_3_11_42_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_43_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"FACIT. https://www.facit.org","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.2147/PROM.S10621","key":"e_1_3_11_44_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2022.21022","key":"e_1_3_11_45_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jiac.2016.05.006","key":"e_1_3_11_46_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2023010348","key":"e_1_3_11_47_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.critrevonc.2009.01.003","key":"e_1_3_11_48_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/cid/ciae487","key":"e_1_3_11_49_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2008.16.4681","key":"e_1_3_11_50_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/0884533614547084","key":"e_1_3_11_51_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/01.tp.0000229419.73428.ff","key":"e_1_3_11_52_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/bmt.2012.158","key":"e_1_3_11_53_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00277-012-1573-4","key":"e_1_3_11_54_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2020.02.017","key":"e_1_3_11_55_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1200/crossmark","alternative-id":["10.1200/JCO-25-00889"],"article-number":"JCO-25-00889","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Clinical Oncology"],"reference-count":54,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,17]]},"references-count":54,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct03016130"}],"short-container-title":["J Clin Oncol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1200/jco-25-00889","is_oa":false,"title":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia","updated":"2025-12-19T02:31:00+00:00","published_date":"2025-12-17","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1200/jco-25-00889","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"condition","value":"Acute Leukemia","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"condition","value":"Hematopoietic Stem-Cell Transplantation","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"modality","value":"Dietary Intervention","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"sample_size","value":"n=214","value_numeric":214},{"paper_doi":"10.1200/jco-25-00889","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"warning","value":"Caloric and nutritional outcomes were not quantified in the abstract.","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"warning","value":"Noninferiority design; classified here under randomized controlled trial.","value_numeric":null},{"paper_doi":"10.1200/jco-25-00889","tag_type":"warning","value":"Trial was stopped early at the second interim analysis.","value_numeric":null}],"summaries":{"what_studied":"A phase III randomized noninferiority trial compared a liberalized diet that allowed fresh fruits and vegetables versus a neutropenic diet in patients undergoing HSCT or induction chemotherapy for acute leukemia, with the primary outcome being any major infection during neutropenia (noninferiority margin ≤10%).","key_result":"The trial stopped at the second interim analysis after 214 evaluable patients: major infections occurred in 31.4% with the liberalized diet versus 20.2% with the neutropenic diet, a difference of 11.2% (95% CI, -0.4 to 22.9).","limitations":"The study was halted early at the second interim analysis with n=214. The abstract does not provide numeric data on caloric intake or nutritional status.","practice_takeaway":"In HSCT and acute leukemia patients during neutropenia, a liberalized diet increased major infections and offered no nutritional benefit; a neutropenic diet remains the safer choice."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Acute Leukemia"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Acute Leukemia"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Acute Leukemia"}}}]]

Papers